Loeb Represents Drugs Made In America Acquisition II in $500 Million IPO

Loeb & Loeb represented Drugs Made In America Acquisition II, a special purpose acquisition company planning to target companies in the pharmaceutical industry, in its $500 million initial public offering.

The company began trading on the Nasdaq Capital Market under the ticker symbol “DMIIU” on September 25, 2025, and closed on September 26. The offering consisted of 50,000,000 units at $10.00 per unit. According to Law360, this marks the largest SPAC listing of 2025 to date.

Once the securities comprising the units begin separate trading, the ordinary shares and rights are expected to be listed on Nasdaq under the symbols "DMII" and "DMIIR," respectively. The underwriters have been granted a 45-day option to purchase up to an additional 7,500,000 units offered by the Company to cover over-allotments, if any.

The Loeb team was led by Mitchell Nussbaum, co-chair of the firm, and Capital Markets partner Alex Weniger-Araujo.

For more information, please see the company’s press release.